Updated: March 31, 2026

TrumpRx

Name: TrumpRx
Brand: TrumpRx
Rating: 0

TrumpRx is a federal prescription savings portal that helps cash-pay patients access lower prices on FDA-approved GLP-1 medications through NovoCare and LillyDirect.

Patient's Rating

0 Reviews

Provider Profile Name: TrumpRx
Website: trumprx.gov
Type: Federal government direct-to-consumer prescription drug price portal; not a pharmacy, telehealth provider, or compounding operation
GLP-1 Products: FDA-approved brand-name semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound) at negotiated Most Favored Nation (MFN) cash prices; no compounded GLP-1 medications
Launched: February 5–6, 2026
Fulfillment Partners: NovoCare Pharmacy (Novo Nordisk) and LillyDirect (Eli Lilly); TrumpRx itself does not dispense medication

About the Provider

President Donald Trump officially launched the TrumpRx website and savings program on February 6, 2026. The platform allows consumers who don’t have or don’t want to use health insurance to purchase many high-cost prescription drugs directly from pharmaceutical companies.

TrumpRx is a price directory that routes users to other sites or coupon redemption paths to access listed cash prices. It does not sell medicines directly, does not prescribe medications or provide telehealth evaluations, and is not a compounded-medication pathway; it lists brand-name drugs with savings routes, not compounded GLP-1 products.

In practical terms, TrumpRx functions as a navigator: patients browse pricing on the portal, are routed to a manufacturer’s direct fulfillment channel (NovoCare for Novo Nordisk products, LillyDirect for Eli Lilly products), complete a telehealth evaluation through the manufacturer’s affiliated provider network, and obtain an FDA-approved prescription medication — not a compounded alternative.

GLP-1 Compounding

TrumpRx does not offer or support compounded GLP-1 medications. All GLP-1 products listed on the platform are FDA-approved brand-name injectables and, as of early 2026, the Wegovy pill (oral semaglutide). Compounded versions are not part of the federal directory.

The launch of TrumpRx on February 5, 2026, advertising access to lower-cost FDA-approved GLP-1 options directly to patients, was widely seen as the context for the accelerated FDA enforcement actions against compounded GLP-1 products that followed in early 2026.

Type of Provider

TrumpRx is a federal government initiative, not a licensed pharmacy. On November 6, 2025, the administration unveiled agreements with the manufacturers of brand-name GLP-1 products that will reduce the prices of the brand-name products when purchased through TrumpRx, a direct-to-consumer platform. The program operates under a Most Favored Nation (MFN) pricing model, tying U.S. cash prices for participating drugs to international benchmarks. Eli Lilly (tirzepatide/Zepbound) and Novo Nordisk (semaglutide/Ozempic, Wegovy) are the primary GLP-1 partners.

GLP-1 Weight Loss

Lose pounds of fat every week
Money Back Guarantee
No membership or hidden fees! Everything you need is included
Start for just $179, no insurance required + free shipping

GLP-1 for Just $179

100k Members HSA/FSA Approved From $179

States Licensed / Available

TrumpRx is a cash-pay platform available to U.S. patients with valid prescriptions. However, purchases do not count toward insurance deductibles or out-of-pocket maximums, so patients with good pharmacy coverage may not benefit. Government beneficiaries — Medicare, Medicaid, TRICARE, VA — are handled separately through dedicated pricing tracks rather than through the standard TrumpRx consumer portal.

Telehealth Providers They Work With

TrumpRx itself does not partner with telehealth providers in the way compounding pharmacies do. Patients still need a valid prescription from a licensed healthcare provider to access TrumpRx pricing. Individual shoppers are transitioned to LillyDirect or NovoCare for fulfillment. Those manufacturer-direct platforms include affiliated telehealth options, but the prescriber relationship is separate from TrumpRx itself.

Pricing from Reviews

Reported discounts available through TrumpRx include reducing monthly costs from approximately $1,000–$1,350 to $350 for Ozempic and Wegovy, and from approximately $1,086 to $346 for Zepbound. The initial price for FDA-approved oral GLP-1 drugs is $150 per month for starting doses.

Monthly costs for Wegovy tablets are available at $149–$299, Wegovy injections at $199–$349, and Zepbound injections at $299–$449 through the TrumpRx portal as of February 2026.

Analysts have noted that the headline savings compare TrumpRx prices to full retail list prices, which most insured patients already do not pay. The practical savings are most meaningful for cash-paying, uninsured patients. Purchases through TrumpRx do not count toward insurance deductibles or out-of-pocket maximums.

Overall Reviews

TrumpRx is too newly launched (February 2026) to have a meaningful patient review record. Industry analysts have noted both its potential benefit for uninsured and underinsured patients and its limitations: no telehealth support is built in, fulfillment requires going through manufacturer-specific channels, and the pricing advantage over existing manufacturer DTC programs (LillyDirect, NovoCare) is modest for many dose levels.

Compounded semaglutide still starts around $199 per month, but many patients now find the $149 Wegovy pill or the $299 Zepbound vial to be a more attractive option due to FDA approval and guaranteed potency. The launch of TrumpRx has materially narrowed the price gap between compounded and brand-name GLP-1 options, which is the most significant downstream effect for the compounding pharmacy market covered in this directory.